Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Mayumi Fujita

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Dermatology
Phone303/724-4045

    Collapse Research 
    Collapse research activities and funding
    R03CA125833     (FUJITA, MAYUMI)Sep 8, 2008 - Aug 31, 2011
    NIH/NCI
    Developing a protocol for profiling blood markers of melanoma
    Role: Principal Investigator

    I01BX001228     (FUJITA, MAYUMI)Jul 1, 2012 - Jun 30, 2016
    VA
    Autoinflammation in Human Melanoma
    Role: Principal Investigator

    R01CA197919     (FUJITA, MAYUMI)Mar 1, 2016 - Feb 28, 2021
    NIH/NCI
    Modulation of inflammasome-mediated cytokine activation by EGCG in human melanoma.
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2016 Apr 12. PMID: 27086916.
      View in: PubMed
    2. Hawkes JE, Nguyen GH, Fujita M, Florell SR, Callis Duffin K, Krueger GG, O'Connell RM. microRNAs in Psoriasis. J Invest Dermatol. 2016 Feb; 136(2):365-71. PMID: 26802234.
      View in: PubMed
    3. Mukherjee N, Schwan JV, Fujita M, Norris DA, Shellman YG. Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol. 2015 Sep; 135(9):2155-61. PMID: 25947358.
      View in: PubMed
    4. Højen JF, Rasmussen TA, Andersen KL, Winckelmann AA, Laursen RR, Gunst JD, Møller HJ, Fujita M, Østergaard L, Søgaard OS, Dinarello CA, Tolstrup M. Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir. Mol Med. 2015 Apr 14; 21:337-45. PMID: 25879630.
      View in: PubMed
    5. Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, Palmer BE, Fujita M, Garlanda C, Mantovani A, Kim S, Dinarello CA. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci U S A. 2015 Feb 24; 112(8):2497-502. PMID: 25654981.
      View in: PubMed
    6. Snedecor ER, Sung CC, Moncayo A, Rothstein BE, Mockler DC, Tonnesen MG, Jones EC, Fujita M, Clark RA, Shroyer KR, Chen J. Loss of primary cilia in melanoma cells is likely independent of proliferation and cell cycle progression. J Invest Dermatol. 2015 May; 135(5):1456-8. PMID: 25629424.
      View in: PubMed
    7. Chen HM, Fujita M. IL-37: a new player in immune tolerance. Cytokine. 2015 Mar; 72(1):113-4. PMID: 25592113.
      View in: PubMed
    8. Nguyen N, Couts KL, Luo Y, Fujita M. Understanding melanoma stem cells. Melanoma Manag. 2015; 2(2):179-188. PMID: 26594315.
      View in: PubMed
    9. Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol. 2015 Mar; 135(3):842-50. PMID: 25350317.
      View in: PubMed
    10. Luo Y, Cai X, Liu S, Wang S, Nold-Petry CA, Nold MF, Bufler P, Norris D, Dinarello CA, Fujita M. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A. 2014 Oct 21; 111(42):15178-83. PMID: 25294929.
      View in: PubMed
    11. Fujita M, Imadome K, Endo S, Shoji Y, Yamada S, Imai T. Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation. FEBS Lett. 2014 Aug 25; 588(17):3240-50. PMID: 25019574.
      View in: PubMed
    12. Luo Y, Nguyen N, Fujita M. Isolation of human melanoma stem cells using ALDH as a marker. Curr Protoc Stem Cell Biol. 2013 Sep 20; 26:Unit 3.8.. PMID: 24510792.
      View in: PubMed
    13. Nguyen N, Luo Y, Fujita M. Aldehyde dehydrogenase isozymes: markers of cancer stem cells in human melanoma. Expert Rev Dermatol. 2013; 8(2):111-113. PMID: 26877760.
      View in: PubMed
    14. Edwards CK, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H, Kawaguchi T, Sakata KM, Cheronis J, Trollinger D, Bankaitis-Davis D, Dinarello CA, Norris DA, Bevilacqua MP, Fujita M, Burmester GR. Combined anti-tumor necrosis factor-a therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone. Front Immunol. 2012; 3:366. PMID: 23264777.
      View in: PubMed
    15. Vasiliou V, Thompson DC, Smith C, Fujita M, Chen Y. Aldehyde dehydrogenases: from eye crystallins to metabolic disease and cancer stem cells. Chem Biol Interact. 2013 Feb 25; 202(1-3):2-10. PMID: 23159885.
      View in: PubMed
    16. Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012 Oct; 30(10):2100-13. PMID: 22887839.
      View in: PubMed
    17. Liu W, Luo Y, Dunn JH, Norris DA, Dinarello CA, Fujita M. Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. J Invest Dermatol. 2013 Feb; 133(2):518-27. PMID: 22931929.
      View in: PubMed
    18. Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, Ahn NG, Fujita M. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-50. PMID: 22622430.
      View in: PubMed
    19. Domenico J, Lucas JJ, Fujita M, Gelfand EW. Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status. Int Arch Allergy Immunol. 2012; 158(2):196-205. PMID: 22286752.
      View in: PubMed
    20. Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG. ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open. 2012 Feb 15; 1(2):92-100. PMID: 23213401.
      View in: PubMed
    21. Dunn JH, Ellis LZ, Fujita M. Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 2012 Jan 01; 314(1):24-33. PMID: 22050907.
      View in: PubMed
    22. Jensen JD, Dunn JH, Luo Y, Liu W, Fujita M, Dellavalle RP. Ellagic acid inhibits melanoma growth in vitro. Dermatol Reports. 2011 Oct 05; 3(3):e36. PMID: 25386288.
      View in: PubMed
    23. Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D, Dunn JH, Fujita M. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1ß secretion. Biochem Biophys Res Commun. 2011 Oct 28; 414(3):551-6. PMID: 21982776.
      View in: PubMed
    24. Reuland SN, Goldstein NB, Partyka KA, Cooper DA, Fujita M, Norris DA, Shellman YG. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. PLoS One. 2011; 6(8):e24294. PMID: 21897876.
      View in: PubMed
    25. Prado R, Jensen JD, Okamoto M, Luo Y, Lewis KD, Fujita M. Metastatic melanoma manifesting with purulent nodules composed of neutrophils and melanoma cells. Eur J Dermatol. 2011 Jul-Aug; 21(4):642-3. PMID: 21840791.
      View in: PubMed
    26. Luo Y, Robinson S, Fujita J, Siconolfi L, Magidson J, Edwards CK, Wassmann K, Storm K, Norris DA, Bankaitis-Davis D, Robinson WA, Fujita M. Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma. PLoS One. 2011; 6(6):e20971. PMID: 21698244.
      View in: PubMed
    27. Prado R, Brice SL, Fukuda S, Hashimoto T, Fujita M. Paraneoplastic pemphigus herpetiformis with IgG antibodies to desmoglein 3 and without mucosal lesions. Arch Dermatol. 2011 Jan; 147(1):67-71. PMID: 21242397.
      View in: PubMed
    28. Anwar A, Norris DA, Fujita M. Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma. Arch Biochem Biophys. 2011 Apr 15; 508(2):198-203. PMID: 21167122.
      View in: PubMed
    29. Jensen JD, Fujita M, Dellavalle RP. Validation of psoriasis clinical severity and outcome measures: searching for a gold standard. Arch Dermatol. 2011 Jan; 147(1):95-8. PMID: 20855674.
      View in: PubMed
    30. Strahan JE, Chorny JA, Cohen JL, Fujita M. Combined multifocal indeterminate cell histiocytosis and basal cell carcinoma. Arch Dermatol. 2010 Mar; 146(3):346-7. PMID: 20231516.
      View in: PubMed
    31. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, Dinarello CA, Fujita M. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem. 2010 Feb 26; 285(9):6477-88. PMID: 20038581.
      View in: PubMed
    32. Strahan JE, Fujita M. A violaceous nodule on the knee. Merkel cell carcinoma (MCC). Arch Dermatol. 2009 Jun; 145(6):715-20. PMID: 19528432.
      View in: PubMed
    33. Fujita M, High WA, Asgari S, Lewis KD, Gonzalez R. Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature. Int J Dermatol. 2009 Apr; 48(4):426-30. PMID: 19335434.
      View in: PubMed
    34. Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol. 2009 Apr; 129(4):964-71. PMID: 18987671.
      View in: PubMed
    35. Goldstein NB, Johannes WU, Gadeliya AV, Green MR, Fujita M, Norris DA, Shellman YG. Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells. J Invest Dermatol. 2009 Feb; 129(2):432-7. PMID: 18668139.
      View in: PubMed
    36. Anwar A, Gu M, Brady S, Qamar L, Behbakht K, Shellman YG, Agarwal R, Norris DA, Horwitz LD, Fujita M. Photoprotective effects of bucillamine against UV-induced damage in an SKH-1 hairless mouse model. Photochem Photobiol. 2008 Mar-Apr; 84(2):477-83. PMID: 18266821.
      View in: PubMed
    37. Riemann H, Takao J, Shellman YG, Hines WA, Edwards CK, Franzusoff A, Norris DA, Fujita M. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Exp Dermatol. 2007 Oct; 16(10):814-22. PMID: 17845213.
      View in: PubMed
    38. Riemann H, Loser K, Beissert S, Fujita M, Schwarz A, Schwarz T, Grabbe S. IL-12 breaks dinitrothiocyanobenzene (DNTB)-mediated tolerance and converts the tolerogen DNTB into an immunogen. J Immunol. 2005 Nov 01; 175(9):5866-74. PMID: 16237079.
      View in: PubMed
    39. Shellman YG, Park YL, Marr DG, Casper K, Xu Y, Fujita M, Swerlick R, Norris DA. Release of vascular endothelial growth factor from a human melanoma cell line, WM35, is induced by hypoxia but not ultraviolet radiation and is potentiated by activated Ras mutation. J Invest Dermatol. 2003 Oct; 121(4):910-7. PMID: 14632212.
      View in: PubMed
    Fujita's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)